Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Equecabtagene autoleucel - Nanjing IASO Biotherapeutics

Next Previous
Drug Profile

Equecabtagene autoleucel - Nanjing IASO Biotherapeutics

Alternative Names: CT-103A; Eque-cel; FUCASO; Fucaso; IBI-326

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing IASO Biotherapeutics
  • Developer Innovent Biologics; Nanjing IASO Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase 0 Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica

Most Recent Events

  • 12 Sep 2025 Preregistration for Multiple myeloma (Second-line therapy or greater) in Saudi Arabia (IV) prior to September 2025
  • 09 Jul 2025 Nanjing IASO Biotechnology plans a phase II trial for Amyloidosis (Newly diagnosed) in July 2025 (IV) (NCT07055724)
  • 09 Jul 2025 Equecabtagene autoleucel receives Orphan Drug status for Multiple myeloma (Second-line therapy or greater) in South Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top